山东大学耳鼻喉眼学报 ›› 2013, Vol. 27 ›› Issue (5): 8-14.doi: 10.6040/j.issn.1673-3770.0.2013.176

• 论著 • 上一篇    下一篇

新辅助化疗联合同期放化疗与同期放化疗单独治疗鼻咽癌疗效及安全性的Meta分析

徐媛媛,曾泉,洪苏玲,胡国华   

  1. 重庆医科大学附属第一医院耳鼻咽喉科, 重庆 400016
  • 收稿日期:2013-06-15 出版日期:2013-10-16 发布日期:2013-10-16
  • 通讯作者: 胡国华,博士生导师。 Email:hghcq@sina.com
  • 作者简介:徐媛媛。 Email:xyycqyk@163.com
  • 基金资助:

    国家临床重点专科建设项目经费卫办医政函[2012]649号

Comparison of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent  chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A meta analysis.

XU Yuan-yuan, ZENG Quan, HONG Su-ling, HU Guo-hua   

  1. Department of Otolaryngology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
  • Received:2013-06-15 Online:2013-10-16 Published:2013-10-16

摘要:

目的    评价新辅助化疗联合同期放化疗(IC+CCRT)治疗局部进展期鼻咽癌的疗效及安全性。方法    计算机检索pubmed、embase、cochrane图书馆、CNKI等数据库有关IC+CCRT与CCRT治疗鼻咽癌的随机对照试验,按照事先设置的标准由两位研究者独立进行筛选、提取相关资料并用RevMan5.1.0软件进行分析。结果    10项RCT共921例患者纳入本研究。Meta分析结果显示,与CCRT相比: ① 近期疗效:IC+CCRT即期颈部淋巴结完全缓解率提高[OR=2.53,95%CI (1.44,4.44),P=0.001],而鼻咽部肿瘤完全缓解率两者差异无统计学意义[OR=1.26,95%CI (0.66,2.40),P=0.16];治疗结束3个月后IC+CCRT鼻咽部肿瘤及颈淋巴结完全缓解率均较前者有所提高[RR=1.07,95%CI(1.02,1.14),P=0.01], [RR=1.11,95%CI (1.02,1.21),P=0.01];②远期疗效:2年总生存率两者差异无统计学意义[OR=1.04, 95%CI(0.97,1.12),P=0.25];③安全性:IC+CCRT治疗过程中除Ⅲ°及以上白细胞下降情况明显外[RR=1.57,95%CI(1.24,1.98),P=0.0002],其余Ⅲ°及以上皮肤反应[RR=1.57,95%CI (0.91,1.96),P=0.14]、口腔黏膜反应   [RR=1.13,95%CI(0.95,1.34),P=0.18]和消化道不良反应[RR=0.99,95%CI (0.72,1.37),P=0.95]两者差异无统计学意义。结论    与CCRT相比,IC+CCRT可以提高近期疗效,但对2年远期总生存率无明显益处,且后者治疗期间白细胞下降更明显。

关键词: 新辅助化疗, 同期放化疗, 鼻咽癌, Meta分析

Abstract:

Objective    To evaluate the efficacy and treatment toxicity of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy compared with concurrent chemoradiotherapy alone in the treatment of locoregionally advanced nasopharyngeal carcinoma. Methods    The search strategy included Pubmed(1978-2013), Embase(1978-2013),the Cochrane Library, China National Knowledge Internet Web (1978-2013), Vipbrowser Database(1978-2013) and Wanfang Database(1978-2013). We also searched reference lists of articles as a complement. RCTs that compared neoadjuvant chemotherapy followed by concurrent chemoradiotherapy(IC+CCRT) with concurrent chemoradiotherapy(CCRT) alone in locoregionally advanced nasopharyngeal carcinoma were included. After study selection, two reviewers assessed and extracted data independently. Meta-analysis was performed by using the RevMan 5.1.0.software. Results    Four studies were included in immediate result of treatment evaluation: compared with CCRT, IC+CCRT got more complete response of cervical lymph nodes[OR=2.53, 95%CI(1.44,4.44)], but had no significant difference between the two groups in the CR of primary lesions (P<0.05). Five studies were included in the short-term efficacy evaluation: compared with the CCRT, IC+CCRT got more complete response of primary lesions and cervical lymph nodes [OR=1.07, 95%CI(1.02,1.14)], [OR=1.11, 95%CI(1.02,1.21)]. Six studies were included in 2 years overall survival evaluation: there had no significant difference between the two groups (P>0.05). There were no treatment-related deaths in both groups of six studies. Ten studies were included in treatment toxicity evaluation: Risk ratios of [OR=1.57, 95%CI(1.24,1.98)], [OR=1.34, 95%CI(0.91,1.96)], [OR=1.13, 95%CI(0.95,1.34)], [OR=0.99, 95%CI(0.72,1.37)]. were observed for leucopenia, dermatitis, mucositis, and gastrointestinal toxicity during the treatment. Conclusion    The neoadjuvant chemotherapy followed by concurrent chemoradiotherapy can improve the shortterm efficacy of treatment but increases the treatment toxicity in local advanced nasopharyngeal carcinoma, and it cannot improve the immediate result and 2-year survival.

Key words: Nasopharyngeal carcinoma, Induced chemotherapy, Neoadjuvant chemotherapy, Chemoradiotherapy

中图分类号: 

  • R739.63
[1] 李仕运,谢艳,潘佳煜,陈美馨,龙丹,张春林. 人工耳蜗植入对老年语后聋患者疗效的Meta分析[J]. 山东大学耳鼻喉眼学报, 2026, 40(3): 20-30.
[2] 林小雪,林葆睿,李佩珊,卢标清. 电子鼻咽镜联合窄带成像技术在鼻咽癌中医辨证中的应用[J]. 山东大学耳鼻喉眼学报, 2026, 40(3): 40-46.
[3] 方璐, 雷玉丹, 王华. 环孢素滴眼液联合玻璃酸钠滴眼液治疗干眼临床效果的Meta分析[J]. 山东大学耳鼻喉眼学报, 2026, 40(2): 65-73.
[4] 雷玉丹,方璐,陈健,彭昌福. 托珠单抗治疗激素抵抗或不耐受的中重度甲状腺相关性眼病临床疗效的Meta分析[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 54-67.
[5] 许雪萌,樊磊,喻望博,蒋芝月,潘晨,黄泳芹. 奥马珠单抗联合特异性免疫治疗变应性鼻炎疗效的Meta分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 26-33.
[6] 王盛,李银丹,杨金姬. microRNA在鼻咽癌中的作用及其研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 125-131.
[7] 邱前辉,肖旭平,杨钦泰,叶菁,邓泽义,王德生,谭国林,蒋卫红,卢永田,唐隽,石照辉,邓晓聪,刘遗斌,王跃武,段传志,杜德坤,白小欣,陈文伙,莫立根,蔡楚伟,曾鹏,何旭英,杨一梅,赵洲洋,陈健龙,赵充,林志雄,李先明,李曙平,陈冬平,陈勇,黄莹,陈春燕,韩非,黄理金,瞿申红. 鼻咽癌治疗后并发颈动脉爆裂综合征的临床处理专家共识[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 1-18.
[8] 王思权,朱洪申,张晓斌,赵洲洋,马跃,杨一梅,黄理金. 放射治疗后鼻咽癌患者单侧颈内动脉栓塞术后脑卒中及颅神经麻痹的相关因素分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 19-25.
[9] 黄巧,任毅,侯涛,廖行伟,朱子昂,詹晓琳,刘盈,尹时华. 鼻咽癌组织中EphB2表达及与临床病理特征的相关性[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 26-30.
[10] 孙春晓,王文晴,岳田,刘济生. 高低累积顺铂剂量同步放化疗治疗鼻咽癌的疗效分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 31-41.
[11] 徐飞,朱光熹,王可心. 基于决策树算法构建鼻咽癌患者放疗后发生放射性口腔黏膜炎风险的预测模型[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 42-48.
[12] 王再兴,唐志元,李定波,石照辉,曾宪海,张秋航. 鼻咽癌放疗后肿瘤复发及颅底骨坏死引起颈内动脉破裂的治疗方案[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 49-58.
[13] 孙芳,谢楚波,邱前辉. 营养指标对鼻咽癌放射性颅底坏死患者创面修复影响的回顾性分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 59-68.
[14] 朱瑞楷,吴家荣,孙芳,谢楚波,邱前辉. 基于计算机断层扫描血管造影术评估鼻咽癌放疗后引起颈内动脉狭窄状况及其影响因素的研究[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 77-84.
[15] 覃德波,薛建成,杨文月,胡兵,陈涛,俞艳萍,孟庆国,孙焕吉,苗北平,卢永田. 鼻咽癌诊疗变革:生物标志物与鼻内镜手术协同推进早期治疗发展[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 85-92.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!